Melanoma Research Victoria

Source: Healio, January 2019 Adjuvant treatment with dabrafenib plus trametinib demonstrated a durable RFS benefit compared with placebo for patients with resected stage III BRAF V600-mutant melanoma, according to long-term follow-up from a randomized phase 3 trial. “Patients with high-risk resectable melanoma represent a broad and diverse group; therefore, there is great clinical interest in […]

Read the full story

Source: The Pharma Letter, December 2018 A triple combination regimen including adoptive T cell therapy, a PIM kinase inhibitor, and a PD-1 inhibitor boosts T cell persistence and improves survival in a mouse model of melanoma, report investigators at the Medical University of South Carolina MEDICAL UNIVERSITY OF SOUTH CAROLINA Adoptive cell transfer (ACT) is […]

Read the full story

Source: OnClive, December 2018 The addition of a novel PD-1 inhibitor to a combination of BRAF inhibitor dabrafenib (Tafinlar) and MEK inhibitor trametinib (Mekinist) is being tested to determine whether the triplet is safe and effective for patients with metastatic or unresectable melanoma. Although the combination of BRAF and MEK inhibitors is already a preferred […]

Read the full story

Source: Immuno-Oncology News, December  2018 A combination of Tavo (tavokinogene telseplasmid/IL-12) and Keytruda(pembrolizumab) was effective at reducing tumors in advanced melanoma patients who had failed prior anti-PD-1 therapies, according to early results of a Phase 2b trial. OncoSec Medical’s Tavo is intended to deliver the immune-stimulating protein interleukin-12 (IL-12) into the tumor microenvironment, inducing controlled and localized production of […]

Read the full story